🇪🇺 Xromi in European Union

EMA authorised Xromi on 1 July 2019

Marketing authorisation

EMA — authorised 1 July 2019

  • Application: EMEA/H/C/004837
  • Marketing authorisation holder: Lipomed GmbH
  • Local brand name: Xromi
  • Indication: Xromi is indicated for the prevention of vaso-occlusive complications of Sickle Cell Disease in patients over 9 months of age.
  • Status: approved

Read official source →

Xromi in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Other Oncology approved in European Union

Frequently asked questions

Is Xromi approved in European Union?

Yes. EMA authorised it on 1 July 2019.

Who is the marketing authorisation holder for Xromi in European Union?

Lipomed GmbH holds the EU marketing authorisation.